Vertex Pharmaceuticals 8-K Filing: Key Insights from December 2024 Report

Here are the key insights extracted from the provided financial report section:

1. Entity Identified: The report pertains to Vertex Pharmaceuticals Incorporated, a company based in Boston, Massachusetts.
2. SEC Identifier: The Central Index Key (CIK) for Vertex Pharmaceuticals is 0000875320.
3. Report Type: This is an 8-K filing, which typically indicates a report of unscheduled material events or corporate changes that are important to shareholders.
4. Filing Date: The report is dated December 20, 2024, indicating the specific date on which the event or information was disclosed.
5. Securities Information: The common stock of Vertex Pharmaceuticals has a par value of $0.01 per share, and it is traded on the NASDAQ under the ticker symbol "VRTX".
6. Contact Information: The company's headquarters is located at 50 Northern Avenue, Boston, MA 02210, and the phone number provided is 617-341-6100.
7. Period Covered: The report references a specific date (December 20, 2024) rather than a range, suggesting it may detail a specific event or disclosure pertinent to that date.
8. Corporate Structure: The text indicates that Vertex Pharmaceuticals is organized under the laws of Massachusetts (MA).

This summary captures the essential information regarding the company and the nature of the filing, which is crucial for investors and analysts reviewing corporate disclosures.